looks like NIH still has concerns about Stem Cell, they might only approve for unmet needs...
This recommendation;
Is driven by the sentence (bolded for emphasis by me) at the end of this paragraph.Rationale for Recommendation
MSCs are investigational products that have been studied extensively for broad clinical applications in regenerative medicine1 and for their immunomodulatory properties.2 No MSCs are approved by the Food and Drug Administration (FDA) for the treatment of COVID-19. There are insufficient data to assess use of MSCs for the treatment of COVID-19.
Wait for the trial to finish, there will most likely be data driven changes shortly afterwards.
Cell Therapy News/Articles, page-4633
-
- There are more pages in this discussion • 13,655 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.065(4.69%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $7.016M | 4.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10425 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 44243 | 5 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |